The new generation of anti-cancer drug lorlatinib is newly launched, please click for detailed consultation!

Lorlatinib is a new generation of ALK (tyrosine kinase) inhibitor specifically used to treat ALK-positive non-small cell lung cancer (NSCLC). ALKPositivity refers to the presence of ALK gene mutation in lung cancer patients. This mutation is a common feature of some non-small cell lung cancer.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For specific medical insurance reimbursement prices, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

As a highly selective targeted drug, lorlatinib interferes with the growth and spread of cancer cells by inhibiting the activity ofALK protein, thereby blocking the development of lung cancer. In addition, lorlatinib also has an inhibitory effect on the ROS1 protein, so it has significant efficacy in the treatment of lung cancer patients with ALK and ROS1 mutations.

Lorlatinib is unique in that it is highly selective against multipleALK mutations, including some that confer resistance to prior therapy. This makes lorlatinib a drug of great interest in first-line treatment, especially for patients who have been treated with other ALK inhibitors, lorlatinib provides a new treatment opportunity.

The development of this drug is based on in-depth molecular biology and genetic research to better understand the pathogenesis of lung cancer. Clinical trial data show that lorlatinib significantly prolongs progression-free survival (PFS) in the treatment of ALKpositive NSCLC patients, providing patients with a longer chance of survival.

Although lorlatinib has shown significant efficacy in treatment, patients still need to be closely monitored during use and make individualized treatment adjustments according to the doctor's recommendations. Lorlatinib may cause some side effects, such as visual disturbances, liver function abnormalities, etc., so regular examinations are required during treatment.